Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

Dean Y. Li & Moderna

1 shared events · Importance 3 · Last updated Aug 19, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
71
Tech
Dean Y. Li: Merck's research president commented on the trial, underscoring the importance of the combination therapy for the company.
Moderna: Moderna is the co-developer of the vaccine and the primary beneficiary, with its stock more than doubling and market cap surging by nearly $40 billion. The trial success validates its mRNA platform and could lead to its entry into the cancer drug market, helping offset declining COVID-19 vaccine sales.
Aug 19, 2026 · 126 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how Dean Y. Li and Moderna interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.